News
-
-
PRESS RELEASE
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
NanoViricides, Inc. to present NV-387, a revolutionary broad-spectrum antiviral drug, at Pharma Partnering Summit 2025. NV-387 mimics virus features to combat viral infections effectively -
-
PRESS RELEASE
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces closing of $6 million offering with healthcare investor. Proceeds for working capital. AGP/Alliance acted as placement agent -
-
PRESS RELEASE
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces securities purchase agreement for $6 million registered direct offering. Proceeds for working capital and corporate purposes -
-
PRESS RELEASE
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
NanoViricides, Inc. receives approval to start Phase II Clinical Trial of NV-387 for MPox treatment in the DRC. NV-387 shows promise as a broad-spectrum antiviral drug -
-
PRESS RELEASE
NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
NanoViricides, Inc. announces Annual Shareholders Meeting to discuss progress on NV-387, a potential treatment for MPox Clade I. Clinical trials underway
